Managed entry agreements for pharmaceutical products in Middle East and North African countries

LAUR Repository

Show simple item record

dc.contributor.author Maskineh, Christiane
dc.contributor.author Nasser, Soumana C.
dc.date.accessioned 2019-11-07T09:44:57Z
dc.date.available 2019-11-07T09:44:57Z
dc.date.copyright 2018 en_US
dc.date.issued 2019-11-07
dc.identifier.issn 2212-1102 en_US
dc.identifier.uri http://hdl.handle.net/10725/11500
dc.description.abstract Objectives The first objective is to describe current managed entry agreement (MEA) activity in the Middle East and North African (MENA) region and the pharmaceutical decision makers’ perception and use of these agreements; The second objective is to describe the challenges as well as to reflect on the uncertainty related to MEAs implementation and the future outlook for MEAs activities in the region. Study Design A prospective cross-sectional survey. Methods A questionnaire was sent to several pharmaceutical manufacturers and public officials involved in pricing and reimbursement of pharmaceuticals in the region. Results Of the 62% of total respondents, 25% were from the public sector, with the remainder from the pharmaceutical (pharma) industry. Only 42% of participants reported having MEAs running in their institutions, the majority representing Lebanon. All respondents reported the use of financial-based agreements, most referring to “discounted treatment” and, to a lesser extent, a “price volume agreement.” Financial-based agreements were reported as either the only type of MEA (71.4%) being used or as being used with outcomes-based agreements (28.6%). The majority of participants ranked challenges in identifying and measuring relevant data as well as the lack of expertise in assessing health economics data. The majority of respondents projected an increase in the use of MEAs to address budget impact while improving access to innovative care. Conclusions Few MENA countries are implementing MEAs, which could be due to lack of data infrastructure as well as a shortage of experts in health economics. Health care stakeholders continue to be optimistic regarding the potential of MEA implementation. en_US
dc.language.iso en en_US
dc.title Managed entry agreements for pharmaceutical products in Middle East and North African countries en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle payer and manufacturer experience and outlook en_US
dc.author.school SOP en_US
dc.author.idnumber 199231640 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal Value in Health Regional Issues en_US
dc.journal.volume 16 en_US
dc.article.pages 33-38 en_US
dc.keywords Financial-based agreements en_US
dc.keywords Health economic en_US
dc.keywords Managed entry agreement en_US
dc.keywords MENA en_US
dc.keywords Outcome-based agreements en_US
dc.keywords Performance-based risk-sharing arrangements en_US
dc.identifier.doi https://doi.org/10.1016/j.vhri.2018.04.003 en_US
dc.identifier.ctation Maskineh, C., & Nasser, S. C. (2018). Managed entry agreements for pharmaceutical products in Middle East and North African countries: payer and manufacturer experience and outlook. Value in health regional issues, 16, 33-38. en_US
dc.author.email soumana.nasser@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.sciencedirect.com/science/article/pii/S2212109918300980 en_US
dc.orcid.id https://orcid.org/0000-0003-4202-7116 en_US
dc.orcid.id https://orcid.org/0000-0003-4202-7116 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account